<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pretreatment evaluation of adults with systemic sclerosis (scleroderma)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pretreatment evaluation of adults with systemic sclerosis (scleroderma)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pretreatment evaluation of adults with systemic sclerosis (scleroderma)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Denton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John S Axford, DSc, MD, FRCP, FRCPCH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 11, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Systemic sclerosis (SSc) encompasses a spectrum of related disorders, most of which share a characteristic clinical feature of skin thickening due to an excess of collagen-containing extracellular matrix within the dermis. The simplest division of the scleroderma-related disorders is into localized and systemic forms of the disease. Localized scleroderma is generally termed "morphea" to avoid confusion with systemic disease  (<a class="graphic graphic_table graphicRef60398" href="/z/d/graphic/60398.html" rel="external">table 1</a>) and is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/13776.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults"</a>.)</p><p>SSc is further classified into major disease subsets based on the extent of skin involvement and the accompanying pattern of internal organ involvement. The principal subsets of SSc are  (<a class="graphic graphic_table graphicRef80559" href="/z/d/graphic/80559.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Diffuse cutaneous systemic sclerosis (dcSSc)</p><p class="bulletIndent1"><span class="glyph">●</span>Limited cutaneous systemic sclerosis (lcSSc)</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic sclerosis sine scleroderma (patients with only internal organ involvement)</p><p class="bulletIndent1"><span class="glyph">●</span>Overlap syndromes (features of systemic sclerosis that coexist with elements of other rheumatic disorders)</p><p></p><p>Treatment decisions for SSc are informed by a thorough pretreatment assessment of the extent and type of organ involvement, which may also help determine whether organ dysfunction is related to potentially reversible inflammation or vasoconstriction (active disease) or due to damage that is irreversible with existing therapies (eg, fibrosis or ischemic necrosis). This topic summarizes the approach to assessing disease activity, organ involvement and damage, and residual function in adults with SSc.</p><p>Overviews of the treatment of SSc in adults and children are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6422.html" rel="external">"Juvenile systemic sclerosis (scleroderma): Classification, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PRETREATMENT EVALUATION</span></p><p class="headingAnchor" id="H3149840628"><span class="h2">General principles</span><span class="headingEndMark"> — </span>The medical history, physical examination, laboratory tests, and imaging studies that lead to an initial diagnosis of systemic sclerosis (SSc) provide much of the information necessary to determine the distribution of organ involvement and thereby guide the pretreatment assessment. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"</a>.)</p><p>In addition, certain autoantibodies found in SSc are associated with subsets of the disease. The presence of some of these autoantibodies may also predict the risk of future organ involvement  (<a class="graphic graphic_table graphicRef59732" href="/z/d/graphic/59732.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Laboratory testing'</a>.)</p><p>An important aspect of contemporary management is careful systematic investigation to define the presence and risk of major organ-based complications at diagnosis [<a href="#rid1">1</a>]. In addition, there should be regular review during follow-up to minimize delays in diagnosis and treatment [<a href="#rid2">2</a>], especially for lung complications such as pulmonary arterial hypertension (PAH) or lung fibrosis [<a href="#rid3">3</a>]. Studies have suggested that proactive screening for complications increases ascertainment and has been associated with improved five-year survival, especially for diffuse cutaneous SSc (dcSSc) [<a href="#rid4">4</a>].</p><p>A multifaceted approach to patient evaluation is necessary in clinical practice, as this provides a much more robust picture of clinically significant manifestations. Composite activity or severity scores for diffuse and limited disease subsets have been developed and validated [<a href="#rid5">5</a>], building upon the Medsger disease severity scale [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H3783132703"><span class="h2">Initial organ-based assessment</span><span class="headingEndMark"> — </span>Assessment of the extent of skin involvement, kidney function, pulmonary function, and the presence or absence of parenchymal lung disease by high-resolution computed tomography (CT) scanning, as well as the estimation of pulmonary arterial pressure by echocardiography, is recommended for all patients who have SSc as part of the initial evaluation. For patients who present in an emergency fashion (eg, with scleroderma renal crisis), some components of the suggested assessment may need to be deferred until the patient is sufficiently stable to undergo the recommended tests and when the presence of acute changes will not compromise the assessment of established cardiac or pulmonary involvement.</p><p class="headingAnchor" id="H3"><span class="h3">Skin involvement</span><span class="headingEndMark"> — </span>An assessment of the distribution and extent of skin involvement must be made prior to the start of treatment and is typically used to determine disease classification  (<a class="graphic graphic_table graphicRef80559" href="/z/d/graphic/80559.html" rel="external">table 2</a>). The distribution and extent of skin involvement may also be valuable for determining prognosis [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults", section on 'Risk factors for increased mortality'</a>.)</p><p>The assessment of skin involvement includes semiquantitative estimation of skin thickness, pliability (hardness), and fixation to underlying structures (tethering). The modified Rodnan skin score (mRSS), which was developed for clinical research, is the most widely used scoring system and may be used in clinical practice to follow the course of cutaneous involvement  (<a class="graphic graphic_figure graphicRef96747" href="/z/d/graphic/96747.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef97759" href="/z/d/graphic/97759.html" rel="external">figure 2</a>). Skin sclerosis is graded at 17 sites, with scores at each site being 0 (normal), 1 (mild thickening), 2 (moderate thickening), or 3 (severe thickening) [<a href="#rid8">8</a>]. It has been standardized for use in clinical trials and research [<a href="#rid9">9</a>].</p><p>When examining the skin, it is generally agreed that rolling skin between index finger and thumb provides the most effective way for estimating thickness of the skin in moving from grades 1 to 3. In late-stage disease, this may be hampered by tethering to underlying structures; grade 3 is completely fixed ("hide-bound"). In practice, standardization between assessors examining the same patients and use of single observers maintain the skin score selected as a valid and useful tool to assess dcSSc. Dermal thickness may be reliably estimated using an ultrasound probe [<a href="#rid10">10</a>], and other tools have been used in clinical trials, such as the durometer. No instrument has outperformed the mRSS in clinical practice.</p><p>The skin score cannot be used as a surrogate index for organ-based involvement, but it may be prognostically valuable. As an example, in one study of 134 patients with diffuse skin involvement, a skin score of 20 or more was the third most powerful predictor of mortality after cardiac and pulmonary involvement (respective odds ratios 4.2, 4.0, and 3.6) [<a href="#rid7">7</a>]. A skin score of 20 or more was also the second most powerful predictor of the development of scleroderma renal crisis. Some studies suggest that combining skin-based subsets and autoantibodies helps better define risk of major complication and is applicable in routine clinical practice [<a href="#rid11">11</a>].</p><p>The role of patient-reported skin scores is an area of interest and may be complementary to other measures of skin involvement. As an example, the coronavirus disease 2019 (COVID-19) pandemic has reduced opportunities for formal assessment of mRSS; thus, a simple patient-reported skin score has been proposed [<a href="#rid12">12</a>]. In addition, to help assess the impact of skin disease on quality of life among patients with SSc, a patient-reported outcome has been developed [<a href="#rid13">13</a>]. Further research is needed to validate these tools and help determine their utility in routine clinical practice.</p><p>Skin involvement in SSc is characterized by variable sclerosis or thickening of the skin. The hands and face are generally the first areas involved, and the hands typically show the most severe changes, especially in the early stages of disease. A more detailed discussion of the cutaneous manifestations of SSc can be found separately. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Cutaneous manifestations'</a>.)</p><p class="headingAnchor" id="H4"><span class="h3">Kidney function</span><span class="headingEndMark"> — </span>Baseline measurement and subsequent periodic monitoring of blood pressure, serum creatinine, estimated glomerular filtration rate (GFR), and an estimate of proteinuria (either from a 24-hour urine collection or a urine protein-to-creatinine ratio) allow patients who have developed, or those who may be developing, scleroderma renal crisis to be identified. A GFR of less than 60 mL/min is considered clinically significant [<a href="#rid14">14</a>]. Classification criteria for scleroderma renal crisis have been proposed to ensure that this important complication can be confidently defined [<a href="#rid15">15</a>]. A calculator (<a class="calc calc_professional" href="/z/d/html/15635.html" rel="external">calculator 1</a>) will calculate the GFR using data from a specific patient. (See  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Pulmonary involvement</span><span class="headingEndMark"> — </span>All patients with suspected SSc should be evaluated for interstitial lung disease and pulmonary hypertension, which are the most frequent types of lung involvement in patients with SSc. A more detailed discussion of the initial evaluation for lung disease in patients with SSc is presented separately (see  <a class="medical medical_review" href="/z/d/html/4368.html" rel="external">"Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma)"</a>). However, we briefly present here the following tests that should be included in the pretreatment assessment:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary function testing (PFT)</strong> – This should be done to assess for the presence or absence of a restrictive ventilatory defect or a decrease in the single breath diffusion capacity for carbon monoxide (DLCO).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiographic imaging of the lung</strong> – High-resolution CT is preferred to a chest radiograph in SSc due to the greater sensitivity of the high-resolution CT. High-resolution CT frequently reveals interstitial lung abnormalities even in patients with normal PFT results.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Doppler echocardiography</strong> – This is recommended for initial screening for PAH. (See  <a class="medical medical_review" href="/z/d/html/8251.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Definition, risk factors, and screening", section on 'Echocardiography'</a>.)</p><p></p><p>In selected patients with abnormal findings suggesting parenchymal lung disease, bronchoalveolar lavage (BAL) or lung biopsy may be necessary to determine whether the abnormalities are due to active inflammation or to fibrotic interstitial lung disease. While available data do not support the utility of routine BAL, it can be of value in selected cases, especially to exclude infection or other pathology [<a href="#rid16">16</a>].</p><p>High-resolution CT has been shown to accurately assess the extent of disease and to predict the histologic subtype [<a href="#rid17">17</a>]. There is a simple staging algorithm for assessing whether lung fibrosis is mild or extensive and whether it has a low or high probability of progression [<a href="#rid18">18</a>]. Although this staging system has been validated in multiple cohorts and is valuable for patients with established lung fibrosis, it is also important to consider patients with subclinical disease who may be at risk for progression. Milder cases of lung involvement with other risk factors for progression are also important to recognize, particularly since more US Food and Drug Administration (FDA)-approved drug treatments are available in the United States [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">"Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)"</a>.)</p><p>Patients with symptoms suggestive of pulmonary hypertension, whose pulmonary arterial pressures cannot be estimated noninvasively (eg, those who have no tricuspid regurgitation), may need right heart catheterization to assess prognosis and to guide treatment. (See  <a class="medical medical_review" href="/z/d/html/8251.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Definition, risk factors, and screening", section on 'Screening'</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Cardiac involvement</span><span class="headingEndMark"> — </span>All patients should have a screening electrocardiogram (ECG). If there is any suspicion of myocarditis or pericarditis, serum creatine kinase (CK) and troponin (either troponin I or troponin T depending upon availability), an ECG, and an echocardiogram are recommended. Cardiac magnetic resonance imaging (MRI) may provide the best tool for identifying myocardial involvement with fibrosis or inflammation, but it is not routinely used [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/120198.html" rel="external">"Cardiac manifestations of systemic sclerosis (scleroderma)", section on 'Screening for cardiac involvement'</a>.)</p><p class="headingAnchor" id="H2211444423"><span class="h2">Additional testing in selected patients</span><span class="headingEndMark"> — </span>The approach to additional testing in patients is largely guided by symptoms and suspected involvement of other organ systems.</p><p class="headingAnchor" id="H3864837977"><span class="h3">Gastrointestinal involvement</span><span class="headingEndMark"> — </span>Patients who have symptoms of dysphagia, constipation, diarrhea, fecal incontinence, weight loss, or evidence of malnutrition should be referred to a gastroenterologist for further evaluation. Esophageal, small bowel, colonic, and anorectal function may be affected in patients with SSc [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/7548.html" rel="external">"Gastrointestinal manifestations of systemic sclerosis (scleroderma)"</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Musculoskeletal involvement</span><span class="headingEndMark"> — </span>Assessment of joint mobility and functional abilities may be necessary to tailor appropriate physical and occupational therapy. Measurement of muscle enzymes (CK and aldolase) is recommended initially to exclude myositis. Repeat testing is needed only if symptoms or physical findings of muscle weakness develop during the course of the disease. If myositis is suspected clinically or on the basis of muscle enzymes elevated more than fourfold, then electromyography and muscle biopsy may be considered. (See  <a class="medical medical_review" href="/z/d/html/127066.html" rel="external">"Overview of and approach to the idiopathic inflammatory myopathies", section on 'Diagnostic approach'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Functional testing</span><span class="headingEndMark"> — </span>It is recommended that a functional assessment tool be used in combination with the broader assessment of disease involvement to encourage a broad approach to management that may mitigate disease impact. Various assessment tools have been proposed for use in both research and clinical practice [<a href="#rid22">22-24</a>]. Scleroderma-specific functional assessment can be measured using the scleroderma health assessment questionnaire (SHAQ); the disability index has been shown to correlate with other outcome measures in clinical trial cohorts [<a href="#rid25">25</a>]. The SHAQ is one of the most widely used tools. Another tool that has been developed is the Systemic Sclerosis Impact of Disease (ScleroID), which is a patient-reported outcome tool that is meant to capture the patient's experience to help guide care [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H1730961120"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118282.html" rel="external">"Society guideline links: Systemic sclerosis (scleroderma)"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Treatment decisions for systemic sclerosis (SSc) are informed by a thorough pretreatment assessment of the extent and type of organ involvement, which may also help determine whether organ dysfunction is related to potentially reversible inflammation or vasoconstriction (active disease) or due to damage that is irreversible with existing therapies (eg, fibrosis or ischemic necrosis). (See <a class="local">'Introduction'</a> above and <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial organ-based assessment</strong> – Assessment of the extent of skin involvement, kidney function, pulmonary function, and the presence or absence of parenchymal lung disease by high-resolution CT scanning, as well as the estimation of pulmonary arterial pressure by echocardiography, is recommended for all patients who have SSc as part of the initial evaluation. (See <a class="local">'Initial organ-based assessment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Skin involvement</strong> – An assessment of the distribution and extent of skin involvement must be made prior to the start of treatment and is typically used to determine disease classification  (<a class="graphic graphic_table graphicRef80559" href="/z/d/graphic/80559.html" rel="external">table 2</a>). The modified Rodnan skin score (mRSS) is the most widely used scoring system to follow the course of cutaneous involvement  (<a class="graphic graphic_figure graphicRef96747" href="/z/d/graphic/96747.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef97759" href="/z/d/graphic/97759.html" rel="external">figure 2</a>). (See <a class="local">'Skin involvement'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Kidney function</strong> – Baseline measurement and subsequent periodic monitoring of blood pressure, serum creatinine, estimated glomerular filtration rate (GFR), and an estimate of proteinuria (either from a 24-hour urine collection or a urine protein-to-creatinine ratio) allow patients who have developed, or those who may be developing, scleroderma renal crisis to be identified. (See <a class="local">'Kidney function'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pulmonary involvement</strong> – All patients with suspected SSc should be evaluated for interstitial lung disease and pulmonary hypertension with pulmonary function testing (PFT), radiographic imaging of the lungs, and doppler echocardiography. (See <a class="local">'Pulmonary involvement'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiac involvement</strong> – All patients should have a screening ECG. Further testing is guided by symptoms. (See <a class="local">'Cardiac involvement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional testing in selected patients</strong> – The approach to additional testing is guided by symptoms and suspected involvement of other organ systems (eg, gastrointestinal and musculoskeletal systems). (See <a class="local">'Additional testing in selected patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Functional testing</strong> – It is recommended that a functional assessment tool be used in combination with the broader assessment of disease involvement to encourage a broad approach to management that may mitigate disease impact. (See <a class="local">'Functional testing'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Denton CP, Hughes M, Gak N, et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology (Oxford) 2016; 55:1906.</a></li><li><a class="nounderline abstract_t">Denton CP, Khanna D. Systemic sclerosis. Lancet 2017; 390:1685.</a></li><li><a class="nounderline abstract_t">Denton CP, Wells AU, Coghlan JG. Major lung complications of systemic sclerosis. Nat Rev Rheumatol 2018; 14:511.</a></li><li><a class="nounderline abstract_t">Nihtyanova SI, Tang EC, Coghlan JG, et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010; 103:109.</a></li><li><a class="nounderline abstract_t">Fasano S, Riccardi A, Messiniti V, et al. Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. Ann Rheum Dis 2019; 78:1681.</a></li><li><a class="nounderline abstract_t">Medsger TA Jr, Silman AJ, Steen VD, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26:2159.</a></li><li><a class="nounderline abstract_t">Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000; 43:2445.</a></li><li><a class="nounderline abstract_t">Black CM. Measurement of skin involvement in scleroderma. J Rheumatol 1995; 22:1217.</a></li><li><a class="nounderline abstract_t">Khanna D, Furst DE, Clements PJ, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord 2017; 2:11.</a></li><li><a class="nounderline abstract_t">Moore TL, Lunt M, McManus B, et al. Seventeen-point dermal ultrasound scoring system--a reliable measure of skin thickness in patients with systemic sclerosis. Rheumatology (Oxford) 2003; 42:1559.</a></li><li><a class="nounderline abstract_t">Nihtyanova SI, Sari A, Harvey JC, et al. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis. Arthritis Rheumatol 2020; 72:465.</a></li><li><a class="nounderline abstract_t">Spierings J, Ong V, Denton CP. PASTUL questionnaire: a tool for self-assessment of scleroderma skin during the COVID-19 pandemic. Ann Rheum Dis 2021; 80:819.</a></li><li><a class="nounderline abstract_t">Man A, Correa JK, Ziemek J, et al. Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis. Ann Rheum Dis 2017; 76:1374.</a></li><li><a class="nounderline abstract_t">Kingdon EJ, Knight CJ, Dustan K, et al. Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment. Rheumatology (Oxford) 2003; 42:26.</a></li><li><a class="nounderline abstract_t">Butler EA, Baron M, Fogo AB, et al. Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. Arthritis Rheumatol 2019; 71:964.</a></li><li><a class="nounderline abstract_t">da Silva SO, da Paz AS, Farias IMVC, et al. Bronchoalveolar Lavage in Systemic Sclerosis Patients: A Systematic Review. Curr Rheumatol Rev 2021; 17:176.</a></li><li><a class="nounderline abstract_t">Desai SR, Veeraraghavan S, Hansell DM, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004; 232:560.</a></li><li><a class="nounderline abstract_t">Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177:1248.</a></li><li><a class="nounderline abstract_t">Khanna D, Lescoat A, Roofeh D, et al. Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice. Arthritis Rheumatol 2022; 74:13.</a></li><li><a class="nounderline abstract_t">Hachulla AL, Launay D, Gaxotte V, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009; 68:1878.</a></li><li><a class="nounderline abstract_t">Kaniecki T, Abdi T, McMahan ZH. Clinical Assessment of Gastrointestinal Involvement in Patients with Systemic Sclerosis. Med Res Arch 2020; 8.</a></li><li><a class="nounderline abstract_t">Smyth AE, MacGregor AJ, Mukerjee D, et al. A cross-sectional comparison of three self-reported functional indices in scleroderma. Rheumatology (Oxford) 2003; 42:732.</a></li><li><a class="nounderline abstract_t">Becker MO, Dobrota R, Garaiman A, et al. Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire. Ann Rheum Dis 2022; 81:507.</a></li><li><a class="nounderline abstract_t">Pope J. Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler's Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud's Condition Score (RCS). Arthritis Care Res (Hoboken) 2011; 63 Suppl 11:S98.</a></li><li><a class="nounderline abstract_t">Clements PJ, Wong WK, Hurwitz EL, et al. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum 2001; 44:653.</a></li></ol></div><div id="topicVersionRevision">Topic 7544 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27284161" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : BSR and BHPR guideline for the treatment of systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28413064" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30111804" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Major lung complications of systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19966313" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31422354" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10529133" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A disease severity scale for systemic sclerosis: development and testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11083267" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7562747" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Measurement of skin involvement in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28516167" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12867579" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Seventeen-point dermal ultrasound scoring system--a reliable measure of skin thickness in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31682743" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33514506" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : PASTUL questionnaire: a tool for self-assessment of scleroderma skin during the COVID-19 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28213563" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12509609" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30614663" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33185168" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Bronchoalveolar Lavage in Systemic Sclerosis Patients: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15286324" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18369202" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Interstitial lung disease in systemic sclerosis: a simple staging system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34313399" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19054830" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34337149" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical Assessment of Gastrointestinal Involvement in Patients with Systemic Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12730528" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A cross-sectional comparison of three self-reported functional indices in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34824049" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22588774" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler's Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud's Condition Score (RCS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11263780" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
